Class / Patent application number | Description | Number of patent applications / Date published |
424940620 | Hyaluronidase or mucinase (3.2.1.35, 3.2.1.36) | 36 |
20080199452 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a Clostridial neurotoxins, to treat various medical conditions, such as overactive bladder, benign prostatic hyperplasia, hyperhidrosis, for example. | 08-21-2008 |
20080199453 | BOTULINUM TOXIN COMPOSITIONS AND METHODS - Disclosed herein are methods of using extracellular matrix digesting enzymes and neurotoxins, such as a | 08-21-2008 |
20080248021 | Use of Hyaluronidase in Combination with Plasmin for the Induction of Posterior Vitreous Detachment - The present invention is directed to compositions and processes related to use of hyaluronidase in combination with plasmin for the induction of posterior vitreous detachment. | 10-09-2008 |
20090311237 | Combination therapy using a soluble hyaluronidase and a bisphosphonate - Provided are combinations, compositions and kits containing a bisphosphonate composition and a soluble hyaluronidase composition formulated for subcutaneous administration. Such products can be used in methods of treating bisphosphonate-treatable diseases or conditions. Also provided are methods for subcutaneous administration of a bisphosphonate compound whereby the dosing regimen is substantially the same as for intravenous administration of the same dosage for treatment of the same bisphosphonate-treatable disease or condition. | 12-17-2009 |
20100003237 | In vivo temporal control of activatable matrix-degrading enzymes - Methods and combinations are provided for controlling the duration of action, in vivo, of matrix-degrading enzymes. The methods and combinations permit temporary in-vivo activation of matrix-degrading enzymes upon administration to the extra cellular matrix (or “ECM”). Matrix-degrading enzymes having a controlled duration of action can be used to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components. | 01-07-2010 |
20100003238 | Modified hyaluronidases and uses in treating hyaluronan-associated diseases and conditions - Provided are combinations, compositions and kits containing a hyaluronan degrading enzyme, such as a soluble hyaluronidase, for treatment of hyaluronan-associated conditions, diseases and disorders. In one example, the products include an additional agent or treatment. Such products can be used in methods for administering the products to treat the hyaluronan-associated diseases and conditions, for example, hyaluronan-associated cancers, for example, hyaluronan-rich tumors. The methods include administration of the hyaluronan degrading enzyme composition alone or in combination with other treatments. Also provided are methods and compositions for providing sustained treatment effects in hyaluronan-associated diseases and conditions. | 01-07-2010 |
20100092450 | Use of Hyaluronidase for the Prevention or Treatment of Arterial Hypertension or Cardiac Insufficiency - The present invention relates to the use of hyaluronidase for the prevention and/or treatment of arterial hypertension or cardiac insufficiency. In addition, the present invention provides a composition and a combined preparation each comprising hyaluronidase and at least one further antihypertensive, and a method of prevention and/or treating arterial hypertension or cardiac insufficiency in a patient in need thereof, wherein the patient is administered a therapeutically effective amount of hyaluronidase. | 04-15-2010 |
20100172892 | HYALURONIDASE AND METHOD OF USE THEREOF - The present invention provides a tnaluronidase. The hyaluronidase can be produced by the strain | 07-08-2010 |
20100266571 | DOSING REGIMENS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISEASES USING PHARMACOLOGICAL CHAPERONES - The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders. | 10-21-2010 |
20100284995 | Temperature sensitive mutants of matrix metalloproteases and uses thereof - Provided are modified matrix metalloprotease (MMP) enzymes that exhibit temperature-dependent activity and uses thereof. The MMPs can be used, for example, to treat ECM-mediated diseases or disorders characterized by increased deposition or accumulation of one or more ECM components. | 11-11-2010 |
20110002909 | METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN - The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject. Also provided is a composition and article of manufacture comprising α1-AT, in particular a formulation suitable for subcutaneous administration of α1-AT. | 01-06-2011 |
20110020314 | IDENTIFYING HAEMATOPOIETIC STEM CELLS BASED ON CELL SURFACE MARKERS - The present invention relates to a method of identifying a haematopoietic stem cell (HSC) or progeny thereof comprising the steps of: obtaining a cell sample including HSC or progeny thereof; detecting the presence of at least one carbohydrate sequence having a sequence of at least one disaccharide repeat of glucuronic acid and N-acetylglucosamine or an equivalent thereof; and identifying a HSC or progeny thereof having the sequence or equivalent thereof. The invention also relates to methods of enriching cell populations for HSC or progeny thereof, for isolating HSC or progeny thereof and cell preparations obtained using the methods of their invention and their uses. | 01-27-2011 |
20110081333 | APPARATUS AND SYSTEM FOR TREATMENT AND PREVENTION OF BAGS UNDER EYES - A simple, safe and effective invention devices for treating bags under the eyes pressure exerting glasses devices, compress badges, bag pressure adhesive strips, cosmetic pressure adhesive strips; to be put on to prevent, and to reduce the bags under the eyes. They are designed to apply antiwrinkle and other cosmetic and therapeutic agents such as hormones, known therapeutic agents, as well as other pharmaceutical, biochemical, nurticeuticals and biological agents, or compounds to enhance the health and beauty of the eye, strengthen the lower eye lids and to treat many oculopathies which can contribute to the condition. They can be used for the eye makeup cosmetically as adjuvant to eye makeup. The electrical stimulation and electromotive force are incorporated in the invention to strengthen the lower eye lids muscles, to improve the health of the eye lids skin and for the delivery of therapeutic agents to treat various oculopathies. | 04-07-2011 |
20110189157 | USE OF HUMAN HYALURONIDASES FOR AXONAL REGROWTH - Chondroitin sulfate proteoglycans (CS-PGs) are axon growth inhibitory molecules present in the glial scar that are responsible (at least in part) for regeneration failure after CNS or spinal cord injury. Removal of chondroitin sulfate glycosamino-glycan chains using the bacterial enzymes chondroitinase-ABC or AC in models of CNS injury promotes both axon regeneration and plasticity. The present invention relates to the use of members of the human hyaluronidase family (endo-beta-acetyl-hexosaminidase enzymes, E.C. 3.2.1.35) for the degradation of chondroitin sulfate (proteoglycans) in the glial scar to promote axonal regrowth in human CNS or spinal cord injury. The present invention also relates to methods for determining endoglycosidase activity, and in particular of the hyaluronidase/chondroitinase type, in a sample, and also relates to methods for detecting compounds that modulate the activity of endoglycosidases and in particular endoglycosidases of the hyaluronidase/chondroitinase type. | 08-04-2011 |
20110212074 | Myeloid colony stimulating factor and uses thereof - The identification of the HYAL 1 hyaluronidase enzyme as a human plasma-derived myeloid colony-stimulating factor (CSF), herein designated CSF5-hyaluronidase, its recombinant production and methods of use are described. This protein may be used for the treatment of myelosuppression as may occur after irradiation, chemotherapy or other diseases where an increase in leukocyte levels may be beneficial. For example, CSF5-may be used to enhance the immune response to viral infection or other diseases associated with immune suppression. | 09-01-2011 |
20110229452 | Ophthalmic Surgical Irrigating Solutions Containing Hyaluronidase - An ophthalmic irrigating solution containing hyaluronidase and an antioxidant is provided. The solution prevents a post-operative intraocular pressure rise when used during an ophthalmic surgical procedure, and also protects corneal endothelial cells. A method for preventing post-operative intraocular pressure increases in an eye during ophthalmic surgery involves irrigating an anterior chamber of the eye with an ophthalmic solution containing hyaluronidase and an antioxidant. Kits containing hyaluronidase and base medium solutions are also provided. The kits are designed such that the hyaluronidase and base medium solution are combined and administered together to an eye of a patient during or following an ophthalmic surgical procedure, such as cataract surgery, intraocular lens surgery, corneal transplant surgery, or glaucoma surgery. Administration of the components of the kit prevents an increase in post-operative intraocular pressure and also protects corneal endothelial cells. | 09-22-2011 |
20120121572 | NEW MEDICINES FOR TOPIC USE BASED ON SULFATED HYALURONIC ACID AS ACTIVATING OR INHIBITING AGENT OF THE CYTOKINE ACTIVITY - The object of the present invention relates to the new and surprising use of sulfated hyaluronic acid (HAS) as regulator agent of the cytokine activity (pro- and anti-inflammatory) and consequently the use of HAS for the preparation of a new medicine for topic use in the prevention and treatment of pathologies associated with the activation and/or deficiency of cytokines of a pro- and anti-inflammatory nature. The Applicant has in fact discovered the exclusive capacity of HAS in modulating the activity of these particular proteins, it has studied the action mechanism and demonstrated the substantial difference between the different sulfated types known in the state of the art, but above all it has demonstrated an unexpectedly high activity of HAS vs different types and strains of Herpes virus, Cytomegalovirus and the virus of vesicular stomatitis. Finally, a further object of the present invention is the use of HAS as a skin absorption promoter of drugs of an anti-inflammatory nature. | 05-17-2012 |
20120164127 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 06-28-2012 |
20120251517 | SUPER FAST-ACTING INSULIN COMPOSITIONS - Provided are methods for control of post-prandial glucose in diabetic subjects by administering a fast-acting insulin analog and a hyaluronidase degrading enzyme. The fast-acting insulin analog and a hyaluronidase are administered between 15 minutes before the meal and 30 minutes after commencing the meal. | 10-04-2012 |
20130022592 | Continuous subcutaneous insulin infusion methods with a hyaluronan-degrading enzyme - Provided are methods for continuous subcutaneous insulin infusion (CSII) that employ a hyaluronan-degrading enzyme, including a recombinant human PH20 (rHuPH20). The methods can be used to more consistently control blood glucose during the course of CSII. The methods can be used to treat subjects having diabetes or other insulin-associated disease or condition. | 01-24-2013 |
20130189242 | Hyaluronidase and Method of use Thereof - The present invention provides a tnaluronidase. The hyaiuronidase can be produced by the strain | 07-25-2013 |
20130202583 | Companion diagnostic for anti-hyaluronan agent therapy and methods of use thereof - Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided. | 08-08-2013 |
20130216517 | STANDARDIZED BEE VENOM PREPARATION - Bee venom may be administered in a standardized formulation with or without relatively small amounts of anesthetic. In particular, the results of the combination of venom and anesthetic dramatically decreased pain and discomfort for patients undergoing apitherapy. | 08-22-2013 |
20140037613 | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases - The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated form of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity. | 02-06-2014 |
20140255384 | METHODS OF TREATING AND PREVENTING SOCIAL COMMUNICATION DISORDER IN PATIENTS BY INTRANASAL ADMINISTRATION OF INSULIN - Methods for delivering an effective amount of insulin to the central nervous system to treat Social Communication Disorder while minimizing systemic exposure to the administered insulin. The present invention provides these advantages by administering at least an effective amount of insulin and/or pharmaceutical composition(s) thereof, to the upper third of the nasal cavity, thereby bypassing the blood-brain barrier and delivering an effective amount of insulin and/or pharmaceutical compound(s) thereof directly to the CNS. Further methods comprise administering an at least an effective amount of therapeutic agents to the amniotic fluid surrounding a fetus with a treatable neurologic agent or a preventable neurologic condition. For example, administering the at least effective amount of insulin to the amniotic fluid of a fetus with a mother diagnosed with gestational diabetes may prevent the fetus from developing Social Communication Disorder or autism. | 09-11-2014 |
20140328826 | PRODUCT AND METHOD FOR TREATING KELOID SCARS, HYPERTROPHIC SCARS AND BURN SCARS WITH CONTRACTURE - A method of treating keloid scars, hypertrophic scars or burn scars with contracture includes administering low molecular weight hyaluronic acid to the keloid scar, hypertrophic scar or burn scar with contracture. | 11-06-2014 |
20140348817 | COMPANION DIAGNOSTIC FOR ANTI-HYALURONAN AGENT THERAPY AND METHODS OF USE THEREOF - Methods and diagnostic agents for identification of subjects for cancer treatment with an anti-hyaluronan agent, such as a hyaluronan-degrading enzyme, are provided. Diagnostic agents for the detection and quantification of hyaluronan in a biological sample and monitoring cancer treatment with an anti-hyaluronan agent, for example a hyaluronan-degrading enzyme, are provided. Combinations and kits for use in practicing the methods also are provided. | 11-27-2014 |
20140356343 | COMPOSITION FOR TREATING PARKINSON'S DISEASE - A composition useful for the treatment of degenerative brain disease. A pharmaceutical composition comprising an effective amount of apamin as an active ingredient and an effective amount of at least another compound including a permeability enhancer and/or carrier molecule. | 12-04-2014 |
20140356344 | MIRAC PROTEINS - This disclosure relates to a method of generating conditionally active biologic proteins from wild type proteins, in particular therapeutic proteins, which are reversibly or irreversibly inactivated at the wild type normal physiological conditions. For example, evolved proteins are virtually inactive at body temperature, but are active at lower temperatures. | 12-04-2014 |
20150010528 | ANESTHETIC COMPOSITION, FORMULATION AND METHOD OF USE - An anesthetic composition for use e.g. in the administration of a local anesthetic by injection comprises a first component, which comprises hyaluronidase, and a second component which comprises an anesthetic preparation. The composition is both effective and highly shelf stable, and has as an advantage that it may be stored and administered at room temperature. In a particular embodiment, the hyaluronidase is prepared in dry powder form, as by lyophilization. The anesthetic component may be selected from a group of known anesthetics, such as lidocaine, polocaine, xylocaine, novocaine, procaine, prilocaine, bupivacaine, mepivacaine, carbocaine, etidocaine and chincocaine. The composition may be prepared in unit dosage forms, including a single dosage form, for a variety of purposes, and such unit dosage forms may be prepared in a plural chambered syringe or like dispenser, whereby the components are not mixed until administration. | 01-08-2015 |
20150010529 | THERMALLY STABLE PH20 HYALURONIDASE VARIANTS AND USES THEREOF - Modified PH20 hyaluronidase polypeptides that exhibit stability and activity under thermal stress conditions are provided. Also provided are compositions and formulations and uses thereof. | 01-08-2015 |
20150023946 | Combined Use of a Sulfated Glycosaminoglycan and a Hyaluronidase for Improving the Bioavailability of Factor VIII - The present invention relates to pharmaceutical preparations comprising Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders. The invention further relates to the combined use of a Factor VIII, a sulfated glycosaminoglycan and a hyaluronidase for the treatment and prevention of bleeding disorders, and to a method for increasing the bioavailability after non-intravenous administration of Factor VIII by co-adminstration of a sulfated glycosaminoglycan and a hyaluronidase. | 01-22-2015 |
20150030583 | Methods of Treating Serosal Cancer - The discovery of clonally pure populations of serosal cancer stem cells (CSCs) as well as methods of producing CSCs, culturing the CSCs and using them in screening assays, has lead to the development of methods of treating serosal and ovarian cancers by targeting removal or inhibition of the glycocalyx coat surrounding such cells, and includes combination therapies using particular chemotherapeutics in conjunction with glycocalyx inhibitors, as well as the same new chemotherapy treatments without targeting the glycocalyx, where the chemotherapeutic agent is any one of LBH-589 (Panobinostat), NVP-AUY922, LAQ824 (NVP-LAQ824, Dacinostat), colchicine, brefeldin A, diphenyleneiodonium chloride, any combination thereof or another agent identified herein. These treatment methods of the invention can also be used in combination with radiation treatment or other conventional cancer therapy. | 01-29-2015 |
20150064161 | PHARMACOLOGICAL VITREOLYSIS - A method of treating or preventing a disorder, or a complication of a disorder, of an eye of a subject comprising contacting a vitreous and/or aqueous humor with a composition comprising a truncated form of plasmin comprising a catalytic domain of plasmin (TPCD). TPCDs include, but are not limited to, miniplasmin, microplasmin and derivatives and variants thereof. The methods of the invention can be used to reduce the viscosity of the vitreous, liquefy the vitreous, induce posterior vitreous detachment, reduce hemorrhagic blood from the eye, clear or reduce materials toxic to the eye, clear or reduce intraocular foreign substances from the eye, increase diffusion of a composition administered to an eye, reduce extraretinal neovascularization and any combinations thereof. The method can be used in the absence of, or as an adjunct to, vitrectomy. | 03-05-2015 |
20150306221 | Mixture of Betamethasone and Tranilast with a Transdermal Gel for Scar Treatment - The present disclosure relates to a synergistic mixture of betamethasone valerate and tranilast combined with a transdermal gel using skin permeation enhancement for application in scars for reducing or preventing the abnormal scar formation, specially keloids and hypertrophic scars. The disclosed synergistic mixture may exhibit permeation enhancing properties. The transdermal gel may include a mixture of silicone, phosphatidylcholine, pracaxi oil, and seje oil; one or more oils having essential fatty acids, behenic acid, oleic acid; one or more skin lipids; a butter having linoleic acid and linolenic acid; and solvents as transdermal penetration enhancers. | 10-29-2015 |
20160022715 | TREATMENT OF INFLAMMATORY CONDITIONS BY MODULATION OF HYALURONAN AND HYALURONIDASE ACTIVITY - The present invention describes compositions and related methods and kits for treating a variety of inflammatory conditions and infections. The therapeutic compositions include certain hyaluronidases capable of generating hyaluronan disaccharides when combined with hyaluronan, and/or the hyaluronan disaccharides themselves, and/or inflammatory hyaluronidase inhibitors. The invention further discloses the use of hyaluronidase inhibitors to treat certain infections in an individual. | 01-28-2016 |